Chromacity secures over £1 Million Seed Follow On Investment from Investors including Eos Advisory
Summary
The 920 helps illuminate collagen, the primary building block of the bodys skin, muscles, bones, tendons and ligaments, and other connective tissues allowing researchers to probe inside living cells by generating a pulse of light as small as 100 femtoseconds in duration. The short pulse brings significant benefits to the user because the period of time the laser is active is very short meaning there is little collateral damage to the sample being examined.Chromacity has also been awarded funding from the Innovate UK programme to create a new monitoring instrument using its patented infra-red laser technology to provide real-time measurements of key greenhouse gases including methane and ethane, as well as ammonia to support the drive towards net zero in agriculture.The company has also confirmed the appointment as CEO of Julian Hayes, a technology business leader who has held directorial positions with Gas Sensing Solutions and Power Photonic, which also trade internationally from Scotland.Julian joins a board that includes industry experts, Robert Black, an experienced executive and non-executive director in the photonics, IT and robotics industries, Richard Laming, a successful academic, founder, executive and non-executive director of technology businesses spanning optoelectronics, MEMS and electronics, and investor director Graham Miller, who is Director of Global Sales and Business Development at Agilent Technologies.Julian Hayes, CEO at Chromacity said: Designing and manufacturing state-of-the-art ultrafast infra-red lasers brings huge value and efficiencies to the global healthcare market. As an existing investor, were excited to see the company make progress towards its goals.Chromacity is a world leader in the design, development, and manufacturing of advanced ultrafast pulsed fibre lasers. The company sells its products either directly, or via a global network of distributors and agents.Eos Advisory LLP is a hands-on, early-stage and growth investor in science and technology innovations that seek to address societal and environmental issues. The 4 impact areas Eos focuses on are 1) Disease Diagnosis, Prevention and Treatment, 2) Food and Water security, 3) Energy Security, Climate Change and Pollution and 4) Improvement and Sustainability of Industrial Processes.Kelvin Capital Ltd is a Scottish based, private investment syndicate, with over 300 UK wide angel investors and a diverse portfolio of 21 investee companies, with a portfolio value of over \xa3240m.The Kelvin Capital team have an extensive knowledge of the early-stage investment market, with over 40 years of experience internally.